What is Karyopharm Therapeutics Inc (KPTI) stock price today?

Karyopharm Therapeutics Inc (KPTI) currently trades at $8.31 per share. The stock has a market capitalization of $195.22M and a P/E ratio of —x.

Is KPTI stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Karyopharm Therapeutics Inc has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Karyopharm Therapeutics Inc's revenue and earnings?

Karyopharm Therapeutics Inc has trailing twelve-month (TTM) revenue of $146.07M with profit margins of -134.20%. Earnings per share (EPS) is $-17.80.

KPTI

Karyopharm Therapeutics Inc

NASDAQ: KPTI · HEALTHCARE · BIOTECHNOLOGY

$8.31

-1.07% today

Updated 2026-04-30

Market cap

$195.22M

P/E ratio

—

P/S ratio

1.34x

EPS (TTM)

$-17.80

Dividend yield

—

52W range

$4 – $11

Volume

1.0M

Market cap

$195.22M

P/E ratio

—

P/S ratio

1.34x

EPS (TTM)

$-17.80

Dividend yield

—

52W range

$4 – $11

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.0

Growth

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$11.00

+32.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 11.60% QoQ

Risks

- Thin margins at -134.20%

- Negative free cash flow $-11.83M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$157.07M	$146.03M	$145.24M	$146.07M	$146.07M
Net income	$-165.29M	$-143.10M	$-76.42M	$-196.04M	$-102.20M
EPS	—	—	—	—	$-17.80
Free cash flow	$-149.67M	$-92.72M	$-127.63M	$-75.37M	$-11.83M
Profit margin	-105.23%	-97.99%	-52.62%	-134.21%	-134.20%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KPTI	$195.22M	29	4.0	2.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Karyopharm Therapeutics Inc trades at $8.31. Our Smart Value Score of 29/100 indicates the stock is weak. TTM revenue stands at $146.07M. with profit margins at -134.20%.

Frequently asked questions

What is Karyopharm Therapeutics Inc's stock price?

Karyopharm Therapeutics Inc (KPTI) trades at $8.31.

Is Karyopharm Therapeutics Inc overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of Karyopharm Therapeutics Inc (KPTI)?

The analyst target price is $11.00, representing +32.4% upside from the current price of $8.31.

What is Karyopharm Therapeutics Inc's revenue?

TTM revenue is $146.07M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.34x

ROE-891.00%

Beta0.40

50D MA$8.15

200D MA$6.55

Shares out0.02B

Float0.02B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KPTI vs LLY →KPTI vs JNJ →KPTI vs ABBV →Stock screener →